SCHEMBL926639

SCHEMBL926639

CC(=O)Nc1nc(C)c(-c2ccc(N)cn2)s1

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 12/20 0.62
PIK3CA P42336 5/20 0.53
PIK3CD O00329 4/20 0.53
PIK3CB P42338 4/20 0.53
PI4KB Q9UBF8 2/20 0.53
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
POLB P06746 1/20 0.52
CLK1 P49759 1/20 0.51
KDM4E B2RXH2 1/20 0.49
NPC1 O15118 1/20 0.49
ALDH1A1 P00352 1/20 0.49
LMNA P02545 1/20 0.49
MAPT P10636 1/20 0.49
HTT P42858 1/20 0.49
RAB9A P51151 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL924659 0.83 PIK3CG (0.64) PIK3CGPIK3CAPIK3CDPIK3CBPI4KB
SCHEMBL4207312 0.82 PIK3CG (0.57) PIK3CGPIK3CAPIK3CDPIK3CBPI4KB
SCHEMBL4213933 0.81 PIK3CG (0.70) PIK3CGPIK3CAPIK3CDPIK3CBPI4KB
SCHEMBL4214047 0.81 PIK3CG (0.59) PIK3CGPIK3CAPIK3CDPIK3CBPI4KB
SCHEMBL48393 0.81 PIK3CG (0.74) PIK3CGPIK3CAPIK3CDPIK3CBMEN1
SCHEMBL927903 0.77 PIK3CG (0.64) PIK3CGPIK3CAPIK3CDPIK3CBPI4KB
SCHEMBL1890923 0.77 PIK3CG (0.60) PIK3CGPIK3CAPIK3CDPIK3CBPI4KB
SCHEMBL4534987 0.77 PIK3CG (1.00) PIK3CGPIK3CAPIK3CDPIK3CBPI4KB
SCHEMBL924832 0.77 PIK3CG (0.60) PIK3CGPIK3CAPIK3CDPIK3CBPI4KB
SCHEMBL925082 0.77 PIK3CG (0.50) PIK3CGPIK3CAPIK3CDPIK3CBPI4KB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7868188-B2 5-heteroaryl thiazoles and their use as PI3K inhibitors ASTRAZENECA AB (SE) 2011-01-11 US disclosed
EP-1841763-B1 5-HETEROARYL THIAZOLES AND THEIR USE AS PI3K INHIBITORS ASTRAZENECA AB (SE) 2010-06-30 EP disclosed
US-20080132502-A1 5-Heteroaryl Thiazoles And Their Use As PI3K Inhibitors ASTRAZENECA AB (SE) 2008-06-05 US disclosed
EP-1841763-A1 5-HETEROARYL THIAZOLES AND THEIR USE AS PI3K INHIBITORS AstraZeneca AB (SE) 2007-10-10 EP disclosed
WO-2006051270-A1 5-HETEROARYL THIAZOLES AND THEIR USE AS P13K INHIBITORS ASTRAZENECA AB (SE) 2006-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132502-A1 5-Heteroaryl Thiazoles And Their Use As PI3K Inhibitors MTOR, PIK3R5, PIK3CA PIK3CG 16/4885PIK3CA 3/4885PIK3CD 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.